Opexa expands IP portfolio

Biopharmaceutical company Opexa Therapeutics has expanded its IP portfolio to include nearly 100 validated patents worldwide, the company has said.

The Texas-based company, which develops personalised immunotherapies for autoimmune disorders, including multiple sclerosis, said it had built a “significant” IP estate.

In a statement issued on Monday (September 29), Opexa said it has also recently received a notice of allowance for Canadian patent 2,459,969, covering its core T-cell technology platform for the development of patient-specific immunotherapies.

It has recently filed a provisional patent application in the US to coincide with the expansion of its technology into B-cell mediated autoimmune disorders, including those with unmet needs, such as neuromyelitis optica (NMO).

“With our recent move into NMO, which is a B-cell mediated disease, we are now pursuing patent coverage that may extend our IP protection across a much broader range of autoimmune disorders,” said Neil Warma, Opexa’s president and chief executive.

Warma added: “This should enhance our position as a leader in the treatment of autoimmune disorders using personalised immunotherapies.”